Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities

In light of the disappointing termination of clinical trials with potent complex I inhibitors, such as IACS-010759, justification for oxidative phosphorylation inhibitors and mitochondrial targeting strategies has been called into question. Consideration of these agents’ potency, tissue selectivity...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:British journal of cancer Ročník 129; číslo 6; s. 897 - 899
Hlavní autori: Machado, Nicole D, Heather, Lisa C, Harris, Adrian L, Higgins, Geoff S
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Nature Publishing Group 05.10.2023
Predmet:
Clinical trials
Electron transport chain
Humans
Inhibitor drugs
Medical research
Mitochondria - metabolism
Oxidative Phosphorylation
Phosphorylation
Targeted cancer therapy
Toxicity
ISSN:0007-0920, 1532-1827, 1532-1827
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:In light of the disappointing termination of clinical trials with potent complex I inhibitors, such as IACS-010759, justification for oxidative phosphorylation inhibitors and mitochondrial targeting strategies has been called into question. Consideration of these agents’ potency, tissue selectivity and toxicity demonstrate what lessons can be learned from this failure and where new opportunities lie.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0007-0920
1532-1827
1532-1827
DOI:10.1038/s41416-023-02394-9